Omron Healthcare, Dr. Oz team up to underscore home blood-pressure monitoring
BANNOCKBURN, Ill. Omron Healthcare has joined forces with "The Dr. Oz Show" in an integrated media partnership to help spread the word about the importance of home blood pressure monitoring, Omron announced Thursday.
“High blood pressure is a growing concern in the United States among adults, and is often referred to as the ‘silent killer,’” stated Ranndy Kellogg, Omron Healthcare VP marketing and product development. “We’re thrilled to align with ‘America’s Doctor’ in the Sept. 7 season premier to help spread the word about the importance of home blood pressure monitoring, further helping to decrease the risk of heart disease and increase life expectancy.”
The Omron Healthcare integration includes a sponsored segment on "The Dr. Oz Show’s" premiere episode, in addition to a consumer incentive that will be revealed by Dr. Oz during the show. The first 50,000 visitors to DoctorOz.com will be able to download a $10 coupon good on any Omron Healthcare home blood pressure monitor at participating retailers.
The second season of "The Dr. Oz Show" will stress to viewers to “Know Your Five,” and blood pressure is one of those lifesaving numbers Americans need to know. As many as 1-in-3 people suffer from high blood pressure, according to the American Heart Association. And, research showed home blood pressure monitoring can be vital to reducing a patient’s risk of stroke, heart attack, heart failure or kidney failure.
Monitoring blood pressure at home is an important measure people can take to reduce their risk of a heart attack or stroke. More than 50% of people with high blood pressure who monitor at home show an improvement in medication compliance and are quicker to take action.
FDA to discuss concerns over medicines with DXM
SILVER SPRING, Md. The Food and Drug Administration last week issued an information packet in preparation for a Sept. 14 advisory committee meeting that will address the potential abuse of dextromethorphan products and whether restrictions should be placed on the sale of those over-the-counter cough medicines.
Members of both the FDA Drug Safety and Risk Management Advisory Committee and the FDA Nonprescription Drugs Advisory Committee will be in attendance at the public meeting.
Included in the 135-page packet is a Drug Enforcement Agency summary of that agency’s concerns over the abuse potential of DXM, a list of substances included as part of the Controlled Substances Act, the approval history and OTC monograph of DXM, abuse-related pharmacology reports, a clinical perspective in the treatment of cough, drug utilization data, Drug Abuse Warning Network data, adverse event reports and a review of the Consumer Healthcare Products Association’s website designed to raise awareness among parents and school authorities around the abuse of nonprescription medicines. According to the docket, the CHPA actively has engaged parents and other groups around effective methods in preventing abuse of OTCs and other medicines since May 2006.
“CHPA does not believe scheduling of dextromethorphan under the Controlled Substances Act is warranted,” the association stated in a 93-page briefing book available to meeting attendees. “The prevalence and scope of reported abuse is limited. CHPA believes that there are more effective interventions to address OTC cough medicine abuse in general, and dextromethorphan abuse in particular, that preserve the significant public health benefit of consumer OTC access to these important cough medicines.”
The abuse of DXM products has been the focus of two previous FDA advisory committees. In August 1990, an advisory committee was convened as a result of reports of abuse of DXM containing cough syrups by teenagers in areas of Pennsylvania and Utah. The committee was asked to help the FDA develop a strategy for assessing the problem and discuss possible solutions. The committee recommended that the sponsor provide additional data on the toxicity of the substance in the higher dose range, and that additional epidemiological data be gathered so that the FDA could better assess the scope and significance of abuse, and the risk to the public health.
In July 1992, the committee reconvened and discussed several proposed epidemiological studies on DXM abuse, including conducting a national survey from interviews with drug-free school coordinators, and evaluating attitudes and behaviors of potential and actual DXM abusers and how they might be affected by an abuse prevention program.
“Although no clear consensus on the extent of the problem or solutions came out of this meeting, there was a general recognition, in this early pre-Internet era, that outbreaks of abuse occurred in small communities, that the DXM abuse problem had not risen yet to the national level and further studies should focus on areas where abuse outbreaks are occurring,” the report, issued by Michael Klein, director of the FDA’s controlled substance staff, read.
NCPA launches PharmacyMatching.com
ALEXANDRIA, Va. In an effort to connect independent pharmacy owners looking to sell their pharmacies and those who seek to purchase them, the National Community Pharmacists Association launched a new website that unites the two.
PharmacyMatching.com helps pharmacists navigate every step of the entrepreneurial process from buying to selling a pharmacy, as part of the association’s focus on increasing the number of independent community pharmacy owners throughout the country, NCPA said.
“Now more than ever, the future of community pharmacy depends on the successful transition of ownership to independent owners,” said NCPA president and pharmacy owner Joseph Harmison. “NCPA wants to be independent pharmacy’s source for matching buyers and sellers to keep independents independent.”